TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Mad Money Opening Bell Lead
Play
JIM CRAMER

Lightning Round Stocks to Buy From Mad Money With Jim Cramer

PRESS RELEASES

MS In Harmony

PRESS RELEASES

Bristol Myers Squibb To Participate In Raymond James Virtual 42nd Annual Institutional Investors Conference

PRESS RELEASES

Bristol Myers Squibb And Celgene Issue Notices Of Redemption And Partial Redemption Of Certain Of Their Senior Notes At "Make Whole" Prices

Mad Money Opening Bell Lead
JIM CRAMER

Lightning Round Stocks to Buy From Mad Money With Jim Cramer

Chinese Biotech CStone On Course To Launch Lung Cancer Drug After Successful Clinical Trial
INVESTING

Heat Biologics Jumps on Progress With Lung-Cancer Drug

PRESS RELEASES

Bristol Myers Squibb Receives European Commission Approval For Inrebic® (fedratinib) For Adult Patients With Newly Diagnosed And Previously Treated Myelofibrosis

CVS Health Isn't Very Healthy
Video

Jim Cramer Looks to Buy Stocks for His Portfolio

  • Feb 7, 2021 12:00 PM EST
PRESS RELEASES

U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene Maraleucel), A New CAR T Cell Therapy For Adults With Relapsed Or Refractory Large B-cell Lymphoma

PRESS RELEASES

Bristol Myers Squibb To Participate In Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day

Wall Street Lead
MARKETS

S&P 500 Closes at Record; Stocks Extend Win Streak to Four

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know
INVESTING

Bristol-Myers Flat After Report - Here's the Must-Hold Support Level

Merck Second-Quarter Results Beat Forecasts
INVESTING

Merck, Bristol Myers Squibb, PayPal, Apple - Thursday's Premarket Movers

Jim Cramer: Bristol-Myers Needs to Slim Down
INVESTING

Bristol-Myers Tops Q4 Earnings Forecast, Boosts 2021 Outlook

Trader New York Stock Exchange Lead
MARKETS

Stimulus Checks, PayPal, Dogecoin, Merck, Ford - 5 Things You Must Know Thursday

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns
INVESTING

Bristol Myers Gains Rights to Rockefeller's Covid Treatment

PRESS RELEASES

Couvet, Switzerland (Photo: Business Wire)

PRESS RELEASES

Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study Showing Superiority Of Deucravacitinib Compared To Placebo And Otezla® (apremilast)

PRESS RELEASES

Bristol Myers Squibb Application For Zeposia® (ozanimod) For The Treatment Of Ulcerative Colitis Accepted For Filing With Priority Review By U.S. Food And Drug Administration

Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters
INVESTING

Dow Futures Rebound, Silver Surges To Seven-Year High As Reddit Retail Army Targets Metals

Ford Is Bringing Back the Bronco SUV and the Ranger Pickup Truck
INVESTING

Morning Bell With Jim Cramer: Buy the Dip in Ford After Earnings

PRESS RELEASES

U.S. Food And Drug Administration Approves OPDIVO® (nivolumab) In Combination With CABOMETYX® (cabozantinib) As First-line Treatment For Patients With Advanced Renal Cell Carcinoma

PRESS RELEASES

U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (nivolumab) As Adjuvant Therapy For Patients With Resected Esophageal Or Gastroesophageal Junction Cancer

Cramer Live 12/15
JIM CRAMER

Accentuate the Positive: Cramer's 'Mad Money' Recap (Monday 1/11/21)

Hang Seng Index Rises With Asian Stocks On Stimulus Bets As Trump Concedes Defeat, Pledges Smooth Handover To Biden
JIM CRAMER

Game Plan: Cramer's 'Mad Money' Recap (Friday 1/8/21)